Journey Medical Corporation Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

LICENSES ACQUIRED (Details)

LICENSES ACQUIRED (Details) $ in Millions, ¥ in Billions					1 Months Ended
LICENSES ACQUIRED (Details) $ in Millions, ¥ in Billions	Nov. 11, 2024 USD ($)	Aug. 31, 2023 USD ($)	Aug. 31, 2023 CNY (¥)	Jun. 29, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jul. 31, 2020 USD ($)
Emrosi Agreement
Assets and Licenses Acquired
Total Upfront payment				$ 10.0
Upfront payment upon execution				3.0
Remaining upfront payment				15.0
Transformation of ownership and all assets of milestone payments				15.0
Threshold additional contingent regulatory and commercial milestone payments payable				$ 150.0
Percentage of reduction in royalty upon launching of competitor products				50.00%
Emrosi Agreement \| Minimum
Assets and Licenses Acquired
Percentage of royalties payable on net sales				10.00%
Emrosi Agreement \| Maximum
Assets and Licenses Acquired
Percentage of royalties payable on net sales				14.00%
Asset purchase agreement \| Qbrexza
Assets and Licenses Acquired
Age of patients					9 years
Asset purchase agreement \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Period of royalty payments					2 years
Asset purchase agreement \| Minimum \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments					30.00%
Asset purchase agreement \| Minimum \| Royalty payment percentage for thereafter \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments					12.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments					40.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for thereafter \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments					19.00%
Asset purchase agreement \| Eli Lilly and Company \| Qbrexza
Assets and Licenses Acquired
Upfront fees					$ 12.5
Milestone payments payable					$ 144.0
License and supply agreement With DRL \| Accutane
Assets and Licenses Acquired
Amount of expense agreed to pay under the agreement						$ 5.0
Contingent amount payable						$ 17.0
Term of accutane						10 years
Termination accutane agreement period						180 days
New License Agreement
Assets and Licenses Acquired
Amount of obligation payment terminated		$ 10.0
Remaining obligation payments		$ 45.0
New License Agreement \| Net sales of at least ¥4 billion (yen)
Assets and Licenses Acquired
Net sales \| ¥			¥ 4
Cutia License Agreement \| Amzeeq
Assets and Licenses Acquired
Milestone payment	$ 1.0
Other revenue	1.0
Milestone payment received, net	$ 1.0